UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231179309-17588359231179309

2023

Link zum Volltext

Verfügbarkeit prüfen

Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer

Société internationale d'urologie journal, 2023-07, Vol.4 (4), p.273-286

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment options for metastatic hormone-sensitive prostate cancer

The lancet oncology, 2022-10, Vol.23 (10), p.1234-1235

2022

Link zum Volltext

Verfügbarkeit prüfen

KIT as a therapeutic target in neuroendocrine prostate cancer

Cancer cell, 2022-11, Vol.40 (11), p.1266-1268

2022

Link zum Volltext

Verfügbarkeit prüfen

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer

World journal of urology, 2023-08, Vol.41 (8), p.2021-2031

2023

Link zum Volltext

Verfügbarkeit prüfen

Combination Strategies and Targeted Radionuclide Therapies

Seminars in nuclear medicine, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [ 177 Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS278-TPS278

2023

Link zum Volltext

Verfügbarkeit prüfen

Modern paradigms for prostate cancer detection and management

Medical journal of Australia, 2022-10, Vol.217 (8), p.424-433

2022

Link zum Volltext

Verfügbarkeit prüfen

Role of FDG PET/CT in Management of Patients with Prostate Cancer

Seminars in nuclear medicine, 2024-01, Vol.54 (1), p.4-13

2024

Link zum Volltext

Verfügbarkeit prüfen

AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [ 177 Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS280-TPS280

2023

Link zum Volltext

Verfügbarkeit prüfen

Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting

International journal of cancer, 2021-07, Vol.149 (2), p.409-419

2021

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapy in metastatic hormone-sensitive prostate cancer

Current opinion in supportive & palliative care, 2022-12, Vol.16 (4), p.234

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of systemic therapy following [ 177 Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.77-77

2023

Link zum Volltext

Verfügbarkeit prüfen

VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [ 161 Tb]Tb-PSMA-I&T

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS281-TPS281

2023

Link zum Volltext

Verfügbarkeit prüfen

Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?

European urology oncology, 2022-10, Vol.5 (5), p.503-504

2022

Link zum Volltext

Verfügbarkeit prüfen

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma

Leukemia & lymphoma, 2017-11, Vol.58 (11), p.2720-2723

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-382

2022

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report

Platelets (Edinburgh), 2015-01, Vol.26 (8), p.809-811

2015

Link zum Volltext

Verfügbarkeit prüfen

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotypeResearch in context

EBioMedicine, 2023-09, Vol.95, p.104738

2023

Link zum Volltext

Verfügbarkeit prüfen

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

EBioMedicine, 2023-09, Vol.95, p.104738-104738, Article 104738

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 532: Circulating tumor DNA and outcomes with lutetium-PSMA in advanced prostate cancer: Preliminary results from an Australian study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.532-532

2022

Link zum Volltext

Verfügbarkeit prüfen

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in medicine, 2022-11, Vol.9

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5614-5614

2023

Link zum Volltext

Verfügbarkeit prüfen

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in medicine, 2022-11, Vol.9

2022

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report

Platelets, 2015, Vol.26 (8), p.809-811

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Berichte
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer

Treatment options for metastatic hormone-sensitive prostate cancer

KIT as a therapeutic target in neuroendocrine prostate cancer

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer

Combination Strategies and Targeted Radionuclide Therapies

LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [ 177 Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Modern paradigms for prostate cancer detection and management

Role of FDG PET/CT in Management of Patients with Prostate Cancer

AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [ 177 Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting

Systemic therapy in metastatic hormone-sensitive prostate cancer

Efficacy of systemic therapy following [ 177 Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [ 161 Tb]Tb-PSMA-I&T

Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotypeResearch in context

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

Abstract 532: Circulating tumor DNA and outcomes with lutetium-PSMA in advanced prostate cancer: Preliminary results from an Australian study

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report

Suchergebnisse filtern